Gregory Batcheller - Xintela AB Executive Chairman of the Board
| XINT Stock | SEK 0.28 0.02 6.67% |
Chairman
Mr. Gregory Batcheller, J.D. was Executive Chairman of the Board of Directors of Xintela AB since March 21, 2017. He was Chairman of the Board since 2011. He is a commercial lawyer, business developer, company director and executive manager with long experience working with pharmaceutical, biotech and medical device companies. He holds a law degree from the University of Toronto, a BS in Economics from the London School of Economics and a LLM from Lund University. He was CEO of Pulsetten AB, which sold DuoCort AB to ViroPharma Inc. in 2011, Partner of PULSE and Member of the Board of AcuCort AB, Dermafol AB and Maas Biolab LLC . Currently, he is Chairman of the Board of NeuroVive Pharmaceutical AB, Monocl AB and A1M Pharma AB, as well as CEO and Chairman of the Board of Stanbridge Corporation BVBA . since 2017.
| Age | 59 |
| Tenure | 7 years |
| Phone | 46 4 62 75 65 00 |
| Web | https://www.xintela.se |
Xintela AB Management Efficiency
The company has return on total asset (ROA) of (1.1374) % which means that it has lost $1.1374 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (4.6888) %, meaning that it generated substantial loss on money invested by shareholders. Xintela AB's management efficiency ratios could be used to measure how well Xintela AB manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Found 4 records | CHAIRMAN Age | ||
| Alan Hulme | Oncopeptides AB | 65 | |
| Bjorn Nilsson | BioInvent International AB | 61 | |
| Per WoldOlsen | Oncopeptides AB | 70 | |
| Peter Benson | Alligator Bioscience AB | 63 | |
Management Performance
| Return On Equity | -4.69 | |||
| Return On Asset | -1.14 |
Xintela AB Leadership Team
Elected by the shareholders, the Xintela AB's board of directors comprises two types of representatives: Xintela AB inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Xintela. The board's role is to monitor Xintela AB's management team and ensure that shareholders' interests are well served. Xintela AB's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Xintela AB's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Peter Edman, Director | ||
| Sven Kili, Director | ||
| Gregory Batcheller, Executive Chairman of the Board | ||
| CarlMagnus Hogerkorp, Production Manager | ||
| Thomas Areschoug, Business Development Manager | ||
| Per Norlen, Chief Officer | ||
| Liselotte Theorell, Director Product Development and Quality Management | ||
| Keld Soendergaard, Director | ||
| Rickard Mosell, Head of Business Development | ||
| Evy LundgrenAkerlund, CEO | ||
| BSc JD, Ex Chairman | ||
| Caroline Ehrencrona, Director Clinical Development and Regulatory Affairs | ||
| Karin Wingstrand, Director | ||
| Adam Lindblom, IR Contact Officer | ||
| Gunnar Telhammar, CFO Director | ||
| Claes Post, Director |
Xintela Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Xintela AB a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -4.69 | |||
| Return On Asset | -1.14 | |||
| Current Valuation | 122.93 M | |||
| Shares Outstanding | 307.57 M | |||
| Shares Owned By Insiders | 58.76 % | |||
| Price To Earning | (4.40) X | |||
| Price To Book | 11.52 X | |||
| Price To Sales | 5,115 X | |||
| Gross Profit | 2.08 M | |||
| EBITDA | (54.43 M) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| LTC | Litecoin | |
| STETH | Staked Ether | |
| LINK | Chainlink |
Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in Xintela AB. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. You can also try the Latest Portfolios module to quick portfolio dashboard that showcases your latest portfolios.
Complementary Tools for Xintela Stock analysis
When running Xintela AB's price analysis, check to measure Xintela AB's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Xintela AB is operating at the current time. Most of Xintela AB's value examination focuses on studying past and present price action to predict the probability of Xintela AB's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Xintela AB's price. Additionally, you may evaluate how the addition of Xintela AB to your portfolios can decrease your overall portfolio volatility.
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios |